Neo-Splicetopes in Tumor Therapy: A Lost Case?

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• The proteasome can generate spliced peptides through reverse proteolysis.
• Spliced peptides recognized by CD8+ T cells have shown promise in melanoma treatment via adoptive T cell transfer (ATT).
• The immune relevance, frequency, and therapeutic applicability of spliced peptides remain subjects of debate.

Purpose of the Study:

• To review current evidence on the immune relevance of spliced peptides (splicetopes).
• To discuss the theoretical potential of tumor-specific splicetopes in cancer therapy.
• To explore the rationale for identifying patient-specific neosplicetopes for ATT.

Main Methods:

• Review of recent scientific literature.
• Theoretical discussion of splicetope function and application.
• Analysis of evidence for and against immune relevance of splicetopes.

Main Results:

• Conflicting evidence exists regarding the immune relevance and therapeutic potential of spliced peptides.
• The identification of spliced peptides has sparked controversy in the scientific community.
• Tumor-specific and patient-specific neosplicetopes are theoretically valuable for ATT.

Conclusions:

• Despite ongoing controversy, spliced peptides hold potential therapeutic value in cancer immunology.
• Further research into tumor-specific neosplicetopes is warranted for advancing adoptive T cell transfer therapies.
• Identifying patient-specific splicetopes could personalize cancer treatment strategies.